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ability to determine cost-effectiveness in specific settings.
While site-specific research will likely be necessary, so is
the need to critically evaluate such literature before
blindly using it for decision-making.
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THE BPE-PIT— AN ADAPTATION OF THE 
BPE-P FOR USE IN A MULTINATIONAL
CLINICAL TRIAL
Eremenco SL1, Martens LL2, Harris R1, Arnold B1, 
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OBJECTIVE: The Benign Prostate Enlargement-Partner
questionnaire (BPE-P) was initially developed to assess
the impact of patient’s Benign Prostatic Hyperplasia
(BPH) on his partner’s quality of life (QOL). The objec-
tive of this study was to adapt the BPE-P for use in the
clinical trial setting, and to linguistically validate the re-
sulting questionnaire in US, Spanish, Canadian English
and Canadian French subjects.
METHODS: The BPE-P was reworded to facilitate use in
a clinical trial, and reviewed by a multidisciplinary team
including clinicians, QOL experts, and linguists. This US
English version was translated according to standard
methodology: 2 forward translations, 1 reconciliation, 1
back-translation by a native English-speaker, 3-4 reviews
by independent bilingual experts, and final reconciliation
by a native-speaking language coordinator. Pilot testing
and cognitive debriefing interviews were performed with
a minimum of 10 subjects per language/country who
were partners of men with BPH.
RESULTS: The following changes were made to the
questionnaire prior to translation: a) recall period of 30
days was incorporated; b) questions were changed to past
tense to reflect the recall period; c) wording on problems
with sex life was changed to sexual satisfaction to better
suit the trial setting and to prevent a response floor effect;
d) responses to the sexual satisfaction and overall QOL
question were revised; e) sexual satisfaction question was
moved to the penultimate item on the scale to better suit
the flow of questions. No significant problems were de-
tected during translation. Subjects found the translations
and their content suitable and relevant to their situation.
The resulting instrument is now called the Benign Prostate
Enlargement-Partner Impact of Treatment scale (BPE-PIT)
to better reflect its adaptation to the clinical trial setting.
CONCLUSION: The BPE-PIT was successfully trans-
lated for use in an international clinical trial. Psychomet-
ric validation of this new instrument remains necessary.
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Urinary problems secondary to benign prostatic hyperpla-
sia (BPH) are found in 20 to 25% of the male population
over 50 years of age. This is thus a public health problem
with a number of diagnostic, therapeutic and economic
facets. The severity of the condition is assessed by the IPSS
score, a well-known and recognized questionnaire.
OBJECTIVE: To evaluate the impact of this male pathol-
ogy on the spouse as part of the growing importance at-
tached to the caregiver.
METHODS: As part of a cohort study conducted be-
tween October 2000 and March 2001, the GP gave the
patient two PFM (Patient Family Measurement) self-
questionnaires for himself and for his spouse. During the
consultation, 36.1% of the patients spontaneously com-
plained of sleep problems.
RESULTS: We are most interested in the impact of day-
time somnolence. The Epworth Scale was used to evaluate
this. The score observed in a control population with nor-
mal sleeping habits is 5.9. For the analysis, we used 482
patient questionnaires and 382 spouse questionnaires. The
rate of return of the spouse questionnaires (80%) was very
satisfactory. The risk of daytime somnolence for the pa-
tient increased with the severity of the urinary problems
with scores of 5.9, 6.4, and 8.9 on the PFM for slight,
moderate, and severe urinary problems respectively. Simi-
larly, for the spouses, the PFM score increased with in-
creasing severity: slight  4.7; moderate  5; severe  7.4.
There is therefore a significant risk of daytime somnolence
among spouses of patients with severe BPH.
CONCLUSION: As it is known that somnolence is re-
sponsible for a third of all road accidents, it is essential
for these patients to limit the severity of their pathology
by undergoing appropriate treatment.
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Urinary problems secondary to benign prostatic hyper-
plasia (BPH) are found in 20 to 25% of the population of
men over 50 years of age. This is therefore a public health
problem with a number of diagnostic, therapeutic and
economic facets. The severity of the problem is assessed
by the score obtained on the IPSS, a well-known and rec-
ognized questionnaire.
OBJECTIVE: As part of the growing importance at-
tached to the caregiver, it is interesting to evaluate the
consequences of this masculine pathology for the spouse.
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METHOD: As part of a cohort study conducted between
10/2000 and 03/2001, GPs gave their patients two Pa-
tient Family Measurement (PFM) self-questionnaires for
himself and his spouse.
RESULTS: For the analysis, 357 patient questionnaires
and 316 spouse questionnaires were used. The rate of re-
turn of the spouse questionnaires (88%) was very satis-
factory. The quality of life (QOL) of the patient was mea-
sured by SF12. The results consisted of two scores:
mental (MCS-12), and physical (PCS-12). The norm ob-
served in the American population, and from which the
scores were standardized, was 50. In patients where the
QOL had deteriorated, all the scores were lower than this
norm, (PCS-12  46, MCS-12  47.2). This deteriora-
tion in the quality of life also applied to the spouse. (PCS-
12  44.4. MCS-12  45.9). For the PCS-12, the differ-
ence was significant.
CONCLUSION: The rate of return of the spouse question-
naires showed the interest and involvement of spouses in
their husband’s pathology. The deterioration in the quality
of life of the spouse highlighted the impact of the disease on
those around him. For both the patient and the spouse, the
quality of life deteriorated with the severity of the BPH.
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OBJECTIVES: To help physicians identify patients most
likely to have erectile dysfunction (ED), we studied the
relationship between ED and health-related correlates
among adult male patients using the Sexual Health In-
ventory for Men (SHIM), a validated five-item question-
naire assessing the presence and severity of ED. The cor-
relates included age, smoker/nonsmoker status, and medical
conditions: diabetes, depression, hypertension, any prostate
disease, and high cholesterol.
METHODS: A convenience sample of patients (N 
31,054) from more than 600 primary care and specialty
physician offices in the US completed the SHIM. ED cor-
responds to a SHIM score 21. Physicians or staff re-
corded medical variables. The risk assessment model for
ED was created using multiple logistic regression analysis
in a 50% random sample (n  15,491) and validated in
the remaining sample (n  15,563).
RESULTS: 61.2% of patients (mean age  53, range 18
to 101 years) had a SHIM score compatible with ED
(mean score 18.5 
 5.68, range from 5 to 25). Probabil-
ity of a SHIM score 21 increased with age (odds ratio
(OR)  1.07/year). Diabetes was the variable most
strongly correlated with a SHIM score compatible with
ED (OR  3.50), followed by depression (OR  2.43),
prostate disease (OR  2.08), hypertension (OR  1.64),
smoking (OR  1.57), and high cholesterol level (OR 
1.52). All ORs were significant (P  .05). The risk assess-
ment model (cutoff P  .5) had good sensitivity (82.2%) and
moderate specificity (59.2%). These statistics were repeat-
able and verified in the remaining half sample during model
validation. Age thresholds were calculated to determine the
patient age beyond which medical conditions increased the
likelihood of ED: diabetes  34 years old; depression  40;
prostate disease  42; hypertension  45; smoking  46;
high cholesterol  46; no medical condition  52.
CONCLUSIONS: Our risk-assessment model was strongly
correlated with a SHIM score compatible with ED. It pro-
vides a simple means of identifying patients likely to have
ED. This information can assist clinicians in questioning
patients and in making appropriate treatment decisions
based on risk factors.
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OBJECTIVE: To assess the cost-effectiveness of the
SPECTRON* hip prosthesis in comparison with the
Charnley for all diagnoses.
METHODS: A Markov model was employed to examine the
cost-effectiveness of the Spectron prosthesis relative to the
commonly used Charnley prosthesis. Revision rates were esti-
mated from patient-level data in the Swedish National Hip
Arthroplasty Register (1992–2000) assuming a constant haz-
ard function in the first instance. Other assumptions included:
a 1% risk of death during a THR procedure; a 4% annual
risk of re-revision following an initial revision; costs of a pri-
mary and revision THR (excluding prosthesis), respectively,
of £3,685 and £4,493 based on data from the Nuffield Or-
thopaedic Centre (NOC). Quality-adjustment weights were
taken from a patient level database at the NOC that mapped
patients into the EQ-5D health index both immediately be-
fore and at one year following hip replacement surgery.
RESULTS: From the Swedish Register, the risk of revision
with the Spectron was 0.38 (95% CI 0.22–0.66) relative to
the Charnley (employing a constant hazard assumption).
This lower revision risk resulted in the Spectron generating
more QALYs than the Charnley, with most of the Spec-
tron’s higher acquisition cost being offset by reduced long-
term costs. The incremental cost per QALY gained with the
Spectron ranged from £300 (95% CI £1000 to £3400) in
younger patients to £1300 (95% CI £600 to £6000) in
older patients. Fitting a more flexible form to the hazard
function that allows for both increasing and decreasing
risks of revision suggests that the Spectron could be both
cost saving and more effective than the Charnley.
CONCLUSION: The costs and QALY results from this
analysis indicate that the Spectron is a cost-effective use
of health-service resources. *‘SPECTRON’ is a trade-
mark of Smith & Nephew.
